Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,000

Document Document Title
WO/2018/096011A1
The invention relates to a method for alkylating an amino compound, characterized in that at least one triazine derivative of general formula (I) or at least one urea or urea derivative of the general formula (II), (II), wherein • R4 a...  
WO/2018/087019A1
The invention relates to a method for producing amide bonds, particularly peptide bonds, with the aid of new amide coupling reagents containing an anion of formula (I); the invention also relates to these new reagents and to the producti...  
WO/2018/080007A1
The present invention relates to a preparation method for removing triuret causing turbidity in urea water and to urea water prepared thereby and, more specifically, to a preparation method wherein urea is introduced to de-ionized water ...  
WO/2018/066646A1
The present invention addresses the problem of finding a novel medicine which has an excellent tryptophanase inhibitory effect, suppresses indoxyl sulfate production in blood to thereby prevent deterioration of renal function, and thus c...  
WO/2018/064559A1
The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose...  
WO/2018/048862A1
The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.  
WO/2018/048871A1
The present invention relates to a newly identified solvate form of (i?)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention furth...  
WO/2018/045229A1
The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.  
WO/2018/033525A1
This invention relates to compounds that are agonists or partial agonists of the histamine site of the NMDA receptor, the method of preparation thereof and applications thereof.  
WO/2018/018091A1
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.  
WO/2018/019987A1
The present invention relates to the medicinal use of small organic compounds, in particular amide and urea derivatives, for the treatment of congenital disorders of glycosylation, and in particular PMM2 congenital disorder of glycosylat...  
WO/2018/007986A1
I n the process of the present invention, cariprazine is prepared by converting (trans-4-amino- cyclohexyl)-acetic acid ethyl ester hydrochloride to trans-4-aminocyclohexyl) acetic acid or its hydrochloride by hydrolysis, from the obtain...  
WO/2018/005625A1
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula (I) or a pharmace...  
WO/2017/188551A1
The present invention relates to a novel N-acylurea derivative and use thereof in the treatment or prevention of cardiovascular diseases and, more particularly, to a novel N-acylurea derivative, a pharmaceutical composition comprising th...  
WO/2017/183723A1
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...  
WO/2017/180323A1
The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide re...  
WO/2017/172761A1
The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPRl a...  
WO/2017/168024A1
The invention relates to polyphenol compounds derived from amide and urea and to the use thereof as antioxidants, as well as to pharmaceutical, cosmetic and food compositions, inter alia, comprising same.  
WO/2017/156164A1
The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present inve...  
WO/2017/154019A1
The present invention relates to an improved process for the preparation of 1,3-bis(2-chloroethyl)-1 -nitrosourea compound of formual-1 which is represented by the following structural formula:  
WO/2017/139414A1
The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases)...  
WO/2017/132023A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing suc...  
WO/2017/099232A1
[Problem] To provide a novel gelling agent containing a mono-urea derivative. [Solution] A gelling agent comprising a compound represented by formula [1] (in the formula, R1 represents a C2-20 straight chain or branched chain alkyl group...  
WO/2017/095969A1
The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the char...  
WO/2017/070482A3
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.  
WO/2017/070482A2
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.  
WO/2017/063091A1
The present disclosure relates to a compound that has biocidal activity or is a precursor of a compound with biocidal activity. The compound comprises an N-halamine precursor, at least one quaternary ammonium and at least one coating-inc...  
WO/2017/062856A1
A synergistic agricultural formula including at least one diacyl or diaryl urea, such as a Ν,Ν'-diformylurea, and at least metal complex, such as metal complexes of cobalt, nickel, silver or other metals, is applied to plants at physio...  
WO/2017/055552A1
The invention relates to the field of polyisocyanate compositions for the production of coatings and adhesives. The composition according to the invention combines a polyisocyanate compound with biuret motifs, a protic, polar reactive di...  
WO/2017/056832A1
Provided is an active-light-sensitive or radiation-sensitive composition that contains (A) a compound having two or more of the structures represented by general formula (1), the compound not having an acid crosslinking group, and (B) a ...  
WO/2017/047572A1
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...  
WO/2017/044314A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...  
WO/2017/043390A1
The present invention provides a method and a device capable of producing urea more efficiently. In the present invention, prior to removing unreacted materials from a urea synthesis solution obtained from a stripper, the pressure of the...  
WO/2017/043391A1
The present invention provides a urea production method and production device, capable of increasing the rate of conversion into urea and decreasing the amount of steam consumed. In the present invention, the reactor temperature is raise...  
WO/2017/040191A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...  
WO/2017/036405A1
A compound having a chemical structure of formula I, wherein n is 0 or 1, X is N or C-R1, R1 is H or Cl, R2 and R3 are independently H, a halogen or an alkyl group, Ar is a substituted or unsubstituted phenylene or naphthylene group, wit...  
WO/2017/038871A1
The purpose of the present invention is to provide a compound having inhibitory activity with respect to the discoidin domain receptor 1. The present invention provides a urea derivative represented by the formula below or a pharmacologi...  
WO/2017/040194A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...  
WO/2017/038873A1
The purpose of the present invention is to provide a compound having inhibitory activity with respect to the discoidin domain receptor 1. The present invention provides a urea derivative represented by the formula below or a pharmacologi...  
WO/2017/031156A1
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymph...  
WO/2017/031156A8
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymph...  
WO/2017/023907A1
The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism o...  
WO/2017/017036A1
The present invention relates to ureaurethanes of the following formula (1) in which at least one of the R1 or R2 radicals is a mono- or polyunsaturated, branched or unbranched alkenyl or alkynyl radical having 12 to 24 carbon atoms, n i...  
WO/2017/016523A1
The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical co...  
WO/2017/013265A1
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...  
WO/2017/011767A3
The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment and prophylaxis of visual h...  
WO/2016/210414A1
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...  
WO/2016/207726A1
The present description provides oligourea catalysts, a polar helical oligomeric strands, and methods for catalyzing reactions with polar helical oligomeric strands and oligourea catalysts. In particular, the invention relates to a polar...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/172425A1
Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)  

Matches 1 - 50 out of 6,000